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Tyrosine kinase inhibitorVandetanib is an orally available tyrosine kinase inhibitor used in the treatment of cancer. The current
synthesis proceeds via an unstable 4-chloroquinazoline, using harsh reagents, in addition to requiring
sequential protection and deprotection steps. In the present work, use of the Dimroth rearrangement
in the key quinazoline forming step enabled the synthesis of Vandetanib in nine steps (compared to
the previously reported 12–14).
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).Introduction
Vandetanib (CaprelsaTM), discovered by AstraZeneca, is an orally
available tyrosine kinase inhibitor with activity against VEGFR2/
EGFR/RET which is currently used in the treatment of medullary
thyroid cancer (Fig. 1).1 Vandetanib is representative of a wide
class of 4-anilinoquinazoline drug molecules that function as ade-
nosine mimetics and bind at the tyrosine kinase intracellular
receptor site; other examples of this compound class include Erlo-
tinib and Gefitinib (Fig. 1).1,2 As part of a programme of work inves-
tigating the use of tyrosine kinase inhibitors (TKI’s) for application
to Positron Emission Tomography (PET) imaging of receptor
expression, the improved synthesis of Vandetanib and related
compounds was investigated.
The current literatureprecedence for the synthesis of Vandetanib
via the quinazolinone intermediate 3 is summarised in Scheme 1
(shown in more detail in ESI, Scheme S1). This is a time-consuming
synthetic strategy involving twelve steps overall and harsh
reagents/reaction conditions. The original synthesis utilised amide
1,3which requirespre-preparationdue toa lackof commercial avail-
ability and Gold’s reagent ([3-(dimethylamino)-2-azaprop-2-en-1-
ylidene]dimethylammonium chloride) to directly construct 3(Scheme 1).4–6 More recent patents have avoided the use of Gold’s
reagent and proceeded via benzoic acid 2; however, this still
involves progression through multiple protection and deprotection
steps.4 The current work reports a new and improved synthesis of
Vandetanib, avoiding quinazolinone 3 and utilising the Dimroth
rearrangement for a streamlined synthetic procedure.7–10Results and discussion
The synthesis commenced from the inexpensive building block
4-hydroxy-3-methoxybenzonitrile 4 (Scheme 2), which was alky-
lated with benzyl bromide in quantitative yield without the need
for extensive purification.11 Nitration of 5 under mild conditions
afforded 6 in 93% yield as a yellow precipitate which required no
further purification.
Literature precedence for the reduction of 6 using iron and
ammonium formate, revealed a difficult work-up associated with
poor yields;12 alternative literature procedures suggested the use
of sodium dithionite.13 Pleasingly, reduction using sodium dithion-
ite gave 7 in 74% yield, with no purification required (Scheme 2).
The synthesis of 8 (Scheme 2 and Table 1) was troublesome due
to the poor solubility of aniline 7 in organic solvents. Ultimately
the reaction was performed neat with a large excess of DMF-
DMA to aid solubility and formation of the formamidine; toluene
was also tested as a co-solvent with no observable effect on the
reaction progress. Microwave irradiation for 15 minutes at 90 C
Scheme 3. Reagents and conditions: i) TFA, microwave (max. power 400 W), 70 C,
45 min; ii) A, Cs2CO3, MeCN, reflux, 3 hr; iii) 4-bromo-2-fluoroaniline, 130 C, 1 h.
Scheme 1. Current synthetic procedure to Vandetanib via the key quinazolinone
intermediate 3.
Scheme 2. Reagents and conditions: i) Benzyl bromide, K2CO3, DMF, rt, 18 h; ii)
Nitric acid, Ac2O, 0 C to rt, 18 h; iii) NaHCO3, tetra-butyl ammonium chloride,
Sodium dithionite, DCM, water, rt, 2 h; iv) DMF-DMA, microwave, 90 C, 15 min.
Fig. 1. Structures of Vandetanib (CaprelsaTM), Gefitinib (IressaTM) and Erlotinib
(TarcevaTM).
1468 K.L. Brocklesby et al. / Tetrahedron Letters 58 (2017) 1467–1469(Entry 1) afforded only minimal conversion to formamidine 8;
however, extension of the reaction time by a further 15 minutes
(to a total of 30 minutes) resulted in an improved yield of 95%
(Entry 5) due to the increased time for solubilisation in DMF-
DMA to occur. Conventional heating (Entry 2) at the same temper-
ature provided 8 in a reduced yield of 58% despite extending the
reaction time to 120 minutes. Of note, on smaller scales chromato-
graphic removal of DMF-DMA was required, but on larger scales
(e.g. 8 mmol) formamidine 8 was observed to precipitate from
DMF-DMA.
TFA mediated debenzylation of 8 was selected owing to the
potential vulnerability to hydrogenation induced reduction of the
formamidine, and afforded 9 in an almost quantitative yield. Alky-
lation of 9 afforded 10 in 58% yield using tert-butyl-4-(tosyloxy)
methyl)piperidine-1-carboxylate (A in Scheme 3), which was syn-
thesised according to a literature method.14
The key Dimroth rearrangement step was then investigated
commencing from 10 in the presence of 4-bromo-3-fluoroaniline
(1 equiv.) and acetic acid with microwave heating at 130 C forTable 1
Optimisation for the synthesis of 8.
Entry Solvent Time (min)
1 DMF-DMA 15
2 DMF-DMA-toluene 120
3 DMF-DMA-toluene 30
4 DMF-DMA-toluene 30
5 DMF-DMA 30
A) Allowed to precipitate overnight; B) Removal of DMF-DMA using silica chromatogra
conditions: 7 (500 mg, 1.97 mmol), either DMF-DMA (3 mL) or DMF-DMA in toluene (1:1,
a maximum power output of 400 W.45 min. No product was observed by either TLC or LCMS when irra-
diated for 15 minutes at 118 C; this contrasted with previous
reports on the synthesis of related 4-anilinoquinazolines such as
Gefitinib.15,16 Duration of the microwave irradiation was irrelevant
for the synthesis of 11, which was temperature dependent and
required 130 C for complete conversion, highlighting the possible
inactivated nature of the reagents. Quinazoline 11 was isolated in
62% yield after chromatographic purification. The proposed mech-
anism for this rearrangement is illustrated in Scheme 4.
The penultimate step in the synthesis of Vandetanib was the
BOC deprotection of piperidine 11. Deprotection according to liter-
ature procedures resulted in low yields during aqueous work-up
(Scheme 5).3 However, through following the literature deprotec-
tion procedure4 and avoiding aqueous work-up, direct silica chro-
matography purification afforded 12 in 83% yield. Reductive
amination with formaldehyde according to the literature proce-
dure4 yielded Vandetanib (CaprelsaTM) in 84% yield, an overall 7%
yield over nine steps.Conclusion
In this report we have presented an alternative route to the syn-
thesis of Vandetanib via the Dimroth rearrangement. Ultimately
this new synthetic procedure is a reduction of three steps com-
pared to the most concise published method and avoids the series
of protection and deprotection steps currently established by sev-
eral literature procedures. Chromatography is only required for
four steps in this synthesis compared to multiple steps in the pre-
vious reports. Overall Vandetanib was synthesised in 7% yield over
9 steps compared to 4–20% yield over 12–14 steps in the previ-
ously reported methods.Experimental
Experimental data can be found in the Supplementary data file
associated with this report. In addition to experimental informa-
tion and characterisation data this file also contains NMR spectra
for selected compounds.Heating (temp(C)) Work-up Yield
Microwave (90 C) A 2%
Conventional (185 C)⁄ None 58%
Microwave (90 C) A 95%
Microwave (90 C) B 94%
Microwave (90 C) A or B 94–95%
phy; ⁄Distillation facilitated removal of DMF-DMA from the product. Reagents and
total volume 3 mL); microwave reactions were conducted in a Biotage Initiator with
Scheme 4. Proposed mechanism for the Dimroth rearrangement; derived from Chandregowdra and co-workers in their synthesis of Erlotinib and Gefitinib.16
Scheme 5. i) TFA, DCM, rt, 2 h; ii) HCHO, AcOH, NaBH(OAc)3, MeOH, DCM, rt, 2 h.
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